These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1256 related items for PubMed ID: 27498387

  • 1. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N.
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [Abstract] [Full Text] [Related]

  • 2. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 3. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
    Asao T, Fujiwara Y, Itahashi K, Kitahara S, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Takahashi K, Ohe Y.
    Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
    [Abstract] [Full Text] [Related]

  • 4. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
    Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N.
    Eur J Cancer; 2021 Mar; 145():183-193. PubMed ID: 33486442
    [Abstract] [Full Text] [Related]

  • 5. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D.
    Oncotarget; 2017 Mar 28; 8(13):21903-21917. PubMed ID: 28423535
    [Abstract] [Full Text] [Related]

  • 6. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 28; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 7. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 28; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 8. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
    Patel A, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M, Singh N, Suresh P, Jain P, Malik PS, Choudhary P, Ganguly S, Khurana S, Ms S, Bothra S, Muthu V, Biswas B.
    Curr Probl Cancer; 2020 Jun 28; 44(3):100571. PubMed ID: 32234264
    [Abstract] [Full Text] [Related]

  • 9. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA.
    J Thorac Oncol; 2014 Apr 28; 9(4):549-53. PubMed ID: 24736079
    [Abstract] [Full Text] [Related]

  • 10. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T.
    Lung Cancer; 2020 Jan 28; 139():195-199. PubMed ID: 31812890
    [Abstract] [Full Text] [Related]

  • 11. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.
    J Thorac Oncol; 2017 Apr 28; 12(4):681-688. PubMed ID: 28007627
    [Abstract] [Full Text] [Related]

  • 12. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.
    Clin Lung Cancer; 2016 Nov 28; 17(6):602-605. PubMed ID: 27405684
    [Abstract] [Full Text] [Related]

  • 13. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N.
    Target Oncol; 2019 Apr 28; 14(2):159-168. PubMed ID: 30895431
    [Abstract] [Full Text] [Related]

  • 14. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J.
    Ann Oncol; 2018 Jun 01; 29(6):1409-1416. PubMed ID: 29668860
    [Abstract] [Full Text] [Related]

  • 15. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B.
    Target Oncol; 2019 Apr 01; 14(2):169-178. PubMed ID: 30888598
    [Abstract] [Full Text] [Related]

  • 16. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 17. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov 01; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 18. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 19. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.
    J Clin Oncol; 2016 Mar 01; 34(7):661-8. PubMed ID: 26598747
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ, Canestaro W, Ravelo A, Wong W.
    J Med Econ; 2017 Jul 01; 20(7):671-677. PubMed ID: 28332433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.